IP Library Granted Patent US 12,343,502
Granted Patent B2
US 12,343,502 · App. 17/933,249 · Granted Jul 1, 2025

System and method for adjusting insulin delivery

Inventors: Bryan Mazlish (Palo Alto, CA); Lane Desborough (Thousand Oaks, CA); Ross Naylor (Fullerton, CA)
Assignee: Insulet Corporation
A61M5/1723A61B5/14532A61B5/4839A61M5/14248A61M5/31568G16H20/17G16H40/63A61K38/28A61M5/003A61M2205/3379A61M2205/35A61M2205/3569A61M2205/3584A61M2205/502A61M2205/52A61M2205/8206A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,502
App. No.
17/933,249
Granted
Jul 1, 2025
Kind
B2
Abstract

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Some methods and systems may be configured to adjust insulin delivery to a person with diabetes according to one or more conditions of an insulin delivery device. Some methods and systems may be configured to enable a lock-out mode where adjustment to insulin delivery to personalize automated insulin delivery is restricted.

Claims (28)

1. An apparatus, comprising:

an insulin delivery device; and

a controller in communication with the insulin delivery device to control provision of insulin to a person with diabetes via the insulin delivery device,

wherein the controller is configured to:

determine a shelf-life risk score for insulin within the insulin delivery device; and

at least partially responsive to the determined shelf-life risk score exceeding a threshold, enabling a lock-out mode for locking out a personalization of one or more user-specific dosage parameters until detection of new insulin within the insulin delivery device.

2. The apparatus of claim 1 , wherein the shelf-life risk score is at least partially based on an age of the undelivered insulin.

3. The apparatus of claim 1 , wherein the shelf-life risk score is at least partially based on blood glucose data following a delivery of the insulin in the insulin delivery device.

4. The apparatus of claim 1 , wherein the controller is configured to control the insulin delivery device to:

deliver insulin at a first point in time according to a first insulin delivery action of a first series of insulin delivery actions of a first insulin delivery profile, the first series of insulin delivery actions including at least one action that includes delivering insulin at a rate larger than a baseline basal insulin rate; and

deliver insulin at a second point in time according to a first insulin delivery action of a second series of insulin delivery actions of a second insulin delivery profile, the second series of insulin delivery actions including delivering insulin at the rate larger than the baseline basal insulin rate,

wherein the shelf-life risk score is at least partially based on a number of times insulin is delivered at the rate larger than the baseline basal insulin rate exceeding a threshold.

5. The apparatus of claim 1 , comprising a mobile application of a smartphone in communication with a reusable control unit.

6. The apparatus of claim 5 , wherein the mobile application is configured to display insulin delivery times.

7. The apparatus of claim 5 , wherein the mobile application is configured to track an amount of undelivered insulin within the insulin delivery device.

8. The apparatus of claim 5 , wherein the mobile application is configured to determine a time of each insulin delivery action of each of the insulin delivery device and a further insulin delivery device.

9. A method, comprising:

determining a shelf-life risk score for insulin within an insulin delivery device; and

locking-out a personalization of one or more user-specific dosage parameters for a user responsive to the shelf-life risk score exceeding a threshold until detection of new insulin within the insulin delivery device.

10. The method of claim 9 , wherein the shelf-life risk score is at least partially based on an age of the undelivered insulin in the insulin delivery device.

11. The method of claim 9 , comprising tracking one or more insulin delivery times for each of the insulin delivery device and a further insulin delivery device.

12. The method of claim 11 , comprising displaying the insulin delivery times on a mobile application in wireless communication with a reusable control unit, the reusable control unit being reversibly connectable to each of the first and the further insulin delivery devices.

13. The method of claim 12 , wherein the mobile application determines the shelf-life risk score based at least in part on blood glucose data that the mobile application receives from a blood glucose sensor for time periods after a delivery of insulin.

14. The method of claim 9 , comprising:

delivering insulin at a first point in time according to a first insulin delivery action of a first series of insulin delivery actions of a first insulin delivery profile, the first series of insulin delivery actions including at least one action that includes delivering insulin at a rate larger than a baseline basal insulin rate; and

delivering insulin at a second point in time according to a first insulin delivery action of a second series of insulin delivery actions of a second insulin delivery profile, the second series of insulin delivery actions including delivering insulin at the rate larger than the baseline basal insulin rate;

wherein the shelf-life risk score is further based on a number of times insulin is delivered at the rate larger than the baseline basal insulin rate exceeding a threshold.

15. The method of claim 9 , comprising generating a message that the shelf-life risk score has exceeded the threshold.

Assignments (3)
SECURITY AGREEMENT SUPPLEMENT Recorded Sep 7, 2023
From: INSULET CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 064840/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2023
From: BIGFOOT BIOMEDICAL, INC.
To: INSULET CORPORATION
Reel/Frame 062900/0001 →
RELEASE OF SECURITY INTEREST Recorded Feb 17, 2023
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 062793/0316 →